Enrollment in clinical trials for novel cancer drugs has reduced drastically since the start of the COVID-19 pandemic. This is due in part to a pause in recruitment on behalf of institutions to curb the spread of the virus as well as increased hesitation from patients themselves. Yourway has an extensive direct-to-patient program, eliminating the need for in-person trial visits, which aids in trial recruitment and retention.